产品
编 号：F055518
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1174277-80-5
产品详情
生物活性：
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2?/? knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP).
体内研究：
Asfotase alfa (0.5-8.2 mg/kg; s.c. once daily for 43 days) shows dose-response relationships that strongly support the pharmacological efficacy for HPP.Animal Model:Akp2?/? knockout mice
Dosage:0.5, 2.0 and 8.2 mg/kg
Administration:Subcutaneous injection; once daily for 43 days
Result:Dose-dependently increased the survival rate of mice, bone mineralization and prevention of mineralization defects of the feet, rib cage, lower limbs, jaw bones, the median survival, body weight, and bone length. Showed a clear relationship between daily dose and achieving a healthy BW and the ED80 (the dose that prevents bone defects in 80% of mice) was 3.2, 2.8 and 2.9 mg/kg/day for these sites. Remained increasing urinary PPi concentrations in all treatment groups.
Asfotase alfa (ENB-0040) is a bone-targeted genetically engineered glycoprotein. Asfotase alfa increases the survival rate, bone mineralization and bone length and prevents mineralization defects of the feet, rib cage, lower limbs, jaw bones in Akp2?/? knockout mice. Asfotase alfa can be used for the research of perinatal, infantile, and juvenile-onset hypophosphatasia (HPP).
体内研究：
Asfotase alfa (0.5-8.2 mg/kg; s.c. once daily for 43 days) shows dose-response relationships that strongly support the pharmacological efficacy for HPP.Animal Model:Akp2?/? knockout mice
Dosage:0.5, 2.0 and 8.2 mg/kg
Administration:Subcutaneous injection; once daily for 43 days
Result:Dose-dependently increased the survival rate of mice, bone mineralization and prevention of mineralization defects of the feet, rib cage, lower limbs, jaw bones, the median survival, body weight, and bone length. Showed a clear relationship between daily dose and achieving a healthy BW and the ED80 (the dose that prevents bone defects in 80% of mice) was 3.2, 2.8 and 2.9 mg/kg/day for these sites. Remained increasing urinary PPi concentrations in all treatment groups.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备